Lifecore Capital Lease Obligations from 2010 to 2024

LFCR Stock   5.84  0.06  1.04%   
Lifecore Biomedical Capital Lease Obligations yearly trend continues to be relatively stable with very little volatility. Capital Lease Obligations is likely to grow to about 14.1 M this year. Capital Lease Obligations is the total obligations of Lifecore Biomedical under capital leases, which are lease agreements that transfer substantially all risks and rewards of ownership to the lessee. View All Fundamentals
 
Capital Lease Obligations  
First Reported
2010-12-31
Previous Quarter
9.9 M
Current Value
14.1 M
Quarterly Volatility
9.1 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Lifecore Biomedical financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lifecore main balance sheet or income statement drivers, such as Depreciation And Amortization of 21.5 M, Interest Expense of 20.8 M or Total Revenue of 323.1 M, as well as many exotic indicators such as Price To Sales Ratio of 0.2, Dividend Yield of 0.0 or PTB Ratio of 0.74. Lifecore financial statements analysis is a perfect complement when working with Lifecore Biomedical Valuation or Volatility modules.
  
This module can also supplement various Lifecore Biomedical Technical models . Check out the analysis of Lifecore Biomedical Correlation against competitors.
To learn how to invest in Lifecore Stock, please use our How to Invest in Lifecore Biomedical guide.

Latest Lifecore Biomedical's Capital Lease Obligations Growth Pattern

Below is the plot of the Capital Lease Obligations of Lifecore Biomedical over the last few years. Lifecore Biomedical capital lease obligations are the amount due for long-term lease agreements that are nearly equivalent to Lifecore Biomedical asset purchases. For example, Lifecore Biomedical can use a capital lease to finance the purchase of an asset without ever buying it. A capital lease gives companies such as Lifecore Biomedical control over an asset for a big portion of its life. It is the total obligations of a company under capital leases, which are lease agreements that transfer substantially all risks and rewards of ownership to the lessee. Lifecore Biomedical's Capital Lease Obligations historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lifecore Biomedical's overall financial position and show how it may be relating to other accounts over time.
Capital Lease Obligations10 Years Trend
Slightly volatile
   Capital Lease Obligations   
       Timeline  

Lifecore Capital Lease Obligations Regression Statistics

Arithmetic Mean9,333,964
Geometric Mean6,525,816
Coefficient Of Variation97.15
Mean Deviation6,962,357
Median3,532,000
Standard Deviation9,068,269
Sample Variance82.2T
Range27.3M
R-Value0.57
Mean Square Error60.2T
R-Squared0.32
Significance0.03
Slope1,147,554
Total Sum of Squares1151.3T

Lifecore Capital Lease Obligations History

202414.1 M
20239.9 M
202211 M
202115 M
202027.5 M
201930.8 M

About Lifecore Biomedical Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Lifecore Biomedical income statement, its balance sheet, and the statement of cash flows. Lifecore Biomedical investors use historical funamental indicators, such as Lifecore Biomedical's Capital Lease Obligations, to determine how well the company is positioned to perform in the future. Although Lifecore Biomedical investors may use each financial statement separately, they are all related. The changes in Lifecore Biomedical's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Lifecore Biomedical's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Lifecore Biomedical Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Lifecore Biomedical. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Capital Lease Obligations9.9 M14.1 M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Lifecore Biomedical is a strong investment it is important to analyze Lifecore Biomedical's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Lifecore Biomedical's future performance. For an informed investment choice regarding Lifecore Stock, refer to the following important reports:
Check out the analysis of Lifecore Biomedical Correlation against competitors.
To learn how to invest in Lifecore Stock, please use our How to Invest in Lifecore Biomedical guide.
Note that the Lifecore Biomedical information on this page should be used as a complementary analysis to other Lifecore Biomedical's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.

Complementary Tools for Lifecore Stock analysis

When running Lifecore Biomedical's price analysis, check to measure Lifecore Biomedical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lifecore Biomedical is operating at the current time. Most of Lifecore Biomedical's value examination focuses on studying past and present price action to predict the probability of Lifecore Biomedical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lifecore Biomedical's price. Additionally, you may evaluate how the addition of Lifecore Biomedical to your portfolios can decrease your overall portfolio volatility.
Stocks Directory
Find actively traded stocks across global markets
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Is Lifecore Biomedical's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lifecore Biomedical. If investors know Lifecore will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lifecore Biomedical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.14)
Revenue Per Share
3.447
Quarterly Revenue Growth
0.208
Return On Assets
(0.05)
Return On Equity
(1.05)
The market value of Lifecore Biomedical is measured differently than its book value, which is the value of Lifecore that is recorded on the company's balance sheet. Investors also form their own opinion of Lifecore Biomedical's value that differs from its market value or its book value, called intrinsic value, which is Lifecore Biomedical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lifecore Biomedical's market value can be influenced by many factors that don't directly affect Lifecore Biomedical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lifecore Biomedical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lifecore Biomedical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lifecore Biomedical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.